Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Abbott Labs (ABT)
The ultimate 360° Tracker Your financial life in one place, automatically

NYSE:ABT

Abbott Labs (ABT)

88.59
+0.18 (0.20%)
as of Jun 18, 2026, 11:52:08 pm Market Open.
234 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Abbott Labs(ABT)

Nov 23, 2010
Recently checked back. Well managed and in good financial shape.
Photo of Don ReedDon Reed
Owned
Unlock Rating
$46.95

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Abbott Labs(ABT)

Nov 19, 2010
Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
No
Unlock Rating
$47.40

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jul 26, 2010
Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$49.24

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

May 27, 2010
The model price is $48.13, a 2% upside only. Fully priced.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$47.87

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 12, 2010
Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
Photo of Gordon ReidGordon ReidUnlock Rating
$49.15

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Apr 26, 2010
Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$50.37

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 14, 2010
Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
Photo of Don LatoDon Lato
Owned
Unlock Rating
$52.31

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Abbott Labs(ABT)

Jan 14, 2010
Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
Photo of David BaskinDavid BaskinUnlock Rating
$55.35

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jan 13, 2010
Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$55.29

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jul 08, 2009
Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$46.31

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Nov 21, 2008
Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
Photo of Walter GerasimowiczWalter Gerasimowicz
Owned
Unlock Rating
$51.52

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Aug 29, 2007
In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
Photo of Norman LevineNorman LevineUnlock Rating
$51.49

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Aug 25, 2005
Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$45.11

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 21, 2004
Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
Photo of Harvey EisenHarvey Eisen
Owned
Unlock Rating
$40.00

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 30, 2004
Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
Photo of David KingDavid KingUnlock Rating
$44.02

Stock price when the opinion was issued

$88.59

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
Showing 166 to 180 of 183 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica